ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 26

Rheumatoid Factor Positivity Increases All-Cause and Cancer Mortality Risk in Korean Healthy Examinees: A Kangbuk Samsung Health Study

Joong Kyong Ahn1, Jiwon Hwang2, Hyemin Jeong3, Ji Young Chae4, Hyungjin Kim3, Hoon-Suk Cha3 and Eun-Mi Koh3, 1Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Department of Medicine, National Police Hospital, Seoul, Korea, The Republic of, 3Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 4Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Cancer, cardiovascular disease and morbidity and mortality, Rheumatoid Factor

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Epidemiology and Public Health - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Several studies have reported increased overall mortality in association with rheumatoid factor (RF) in RA. However, the clinical significance including health outcomes of RF in general populations are incompletely known. Thus, the aim of this study was to determine the association of RF with mortality due to all-causes, cardiovascular disease (CVD), and cancer-cause in Koreans without RA participating in a health-screening program. Furthermore, we analyzed whether the titers of RF had implication for the mortality outcome in healthy screening subjects.

Methods:  A cohort study was performed in 295,837 participants free of osteoarthritis or rheumatoid arthritis (RA), and who had undergone health screening between 2002 and 2012 and been followed-up to determine the risk of all-cause, CVD, and cancer-specific mortality with respect to the presence or titer of RF. To determine whether the participants were deceased, we used National Death Index death certificates.

Results:  The prevalence of RF positivity (≥ 20 IU/mL) was 4.4%. During 1,447,403 person-years of follow-up, 1,402 participants died. Comparing subjects with RF-negativity with those positive for RF in a sex-adjusted model, the HRs for all-cause and cancer mortality were 1.66 (95% CI = 1.39–1.98) and 1.84 (95% CI = 1.44–2.35), respectively. After adjusting for confounding factors, RF positivity was still significantly associated with the risk for all-cause or cancer mortality (HR=1.50, 95% CI = 1.19–1.90; HR=1.56, 95% CI = 1.12–2.16, respectively). However, the HR for cardiovascular mortality was not higher in subjects with RF-positivity than in those with RF-negativity (HR=0.98, 95% CI=0.45–2.11). The HRs for all-cause, CVD, and cancer mortality were estimated in terms of RF levels. After adjusting for confounding factors, all-cause and cancer mortality risk was significantly greater in subjects with an RF titer greater than 100 IU/mL than in those with RF-negativity (HR=2.68, 95% CI=1.72–4.19; HR=2.89, 95% CI=1.58–5.28, respectively). On the other hand, RF titer did not show significant association with an increased risk of CVD mortality.

Conclusion:  In healthy South Korean examinees without RA, RF was associated with a greater risk of all-cause and cancer mortality, suggesting that it predicts greater mortality, even among the apparently healthy population. This result would shed new light on the clinical significance of RF on mortality in the general populations.


Disclosure: J. K. Ahn, None; J. Hwang, None; H. Jeong, None; J. Y. Chae, None; H. Kim, None; H. S. Cha, None; E. M. Koh, None.

To cite this abstract in AMA style:

Ahn JK, Hwang J, Jeong H, Chae JY, Kim H, Cha HS, Koh EM. Rheumatoid Factor Positivity Increases All-Cause and Cancer Mortality Risk in Korean Healthy Examinees: A Kangbuk Samsung Health Study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/rheumatoid-factor-positivity-increases-all-cause-and-cancer-mortality-risk-in-korean-healthy-examinees-a-kangbuk-samsung-health-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-factor-positivity-increases-all-cause-and-cancer-mortality-risk-in-korean-healthy-examinees-a-kangbuk-samsung-health-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology